EVELO BIOSCIENCES INC (EVLO) Fundamental Analysis & Valuation

NASDAQ:EVLO • US2997342025

Current stock price

0.3165 USD
-0.05 (-14.46%)
At close:
0.3159 USD
0 (-0.19%)
After Hours:

This EVLO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. EVLO Profitability Analysis

1.1 Basic Checks

  • EVLO had negative earnings in the past year.
  • EVLO had a negative operating cash flow in the past year.
EVLO Yearly Net Income VS EBIT VS OCF VS FCFEVLO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -399.71%, EVLO is doing worse than 97.84% of the companies in the same industry.
Industry RankSector Rank
ROA -399.71%
ROE N/A
ROIC N/A
ROA(3y)-140.08%
ROA(5y)-110.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVLO Yearly ROA, ROE, ROICEVLO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 0 1K -1K 2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for EVLO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EVLO Yearly Profit, Operating, Gross MarginsEVLO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. EVLO Health Analysis

2.1 Basic Checks

  • EVLO has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for EVLO is higher compared to a year ago.
EVLO Yearly Shares OutstandingEVLO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M 4M 5M
EVLO Yearly Total Debt VS Total AssetsEVLO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

  • Based on the Altman-Z score of -53.01, we must say that EVLO is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of EVLO (-53.01) is worse than 97.01% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -53.01
ROIC/WACCN/A
WACCN/A
EVLO Yearly LT Debt VS Equity VS FCFEVLO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M 100M -100M

2.3 Liquidity

  • A Current Ratio of 0.47 indicates that EVLO may have some problems paying its short term obligations.
  • The Current ratio of EVLO (0.47) is worse than 95.02% of its industry peers.
  • A Quick Ratio of 0.47 indicates that EVLO may have some problems paying its short term obligations.
  • EVLO has a Quick ratio of 0.47. This is amonst the worse of the industry: EVLO underperforms 94.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.47
Quick Ratio 0.47
EVLO Yearly Current Assets VS Current LiabilitesEVLO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EVLO Growth Analysis

3.1 Past

  • EVLO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -131.81%.
EPS 1Y (TTM)-131.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 14.98% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y85.07%
EPS Next 2Y38.62%
EPS Next 3Y24.47%
EPS Next 5Y14.98%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EVLO Yearly Revenue VS EstimatesEVLO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 20M 40M 60M 80M 100M
EVLO Yearly EPS VS EstimatesEVLO Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

1

4. EVLO Valuation Analysis

4.1 Price/Earnings Ratio

  • EVLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year EVLO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVLO Price Earnings VS Forward Price EarningsEVLO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVLO Per share dataEVLO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15 -20 -25

4.3 Compensation for Growth

  • A more expensive valuation may be justified as EVLO's earnings are expected to grow with 24.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.62%
EPS Next 3Y24.47%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EVLO Dividend Analysis

5.1 Amount

  • EVLO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

EVLO Fundamentals: All Metrics, Ratios and Statistics

EVELO BIOSCIENCES INC

NASDAQ:EVLO (12/11/2023, 8:00:02 PM)

After market: 0.3159 0 (-0.19%)

0.3165

-0.05 (-14.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09
Earnings (Next)03-14
Inst Owners0.14%
Inst Owner Change0%
Ins Owners17.39%
Ins Owner Change0%
Market Cap5.99M
Revenue(TTM)N/A
Net Income(TTM)-82.34M
Analysts45.71
Price Target10.2 (3122.75%)
Short Float %0.04%
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)53.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-16.9%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-29
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-3.91
FCFYN/A
OCF(TTM)-3.89
OCFYN/A
SpS0
BVpS-1.41
TBVpS-1.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -399.71%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-140.08%
ROA(5y)-110.47%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.59%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.47
Quick Ratio 0.47
Altman-Z -53.01
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.53%
Cap/Depr(5y)123.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-131.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%87.46%
EPS Next Y85.07%
EPS Next 2Y38.62%
EPS Next 3Y24.47%
EPS Next 5Y14.98%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y35.33%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.33%
EBIT Next 3Y7.12%
EBIT Next 5YN/A
FCF growth 1Y17.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y16.09%
OCF growth 3YN/A
OCF growth 5YN/A

EVELO BIOSCIENCES INC / EVLO Fundamental Analysis FAQ

What is the fundamental rating for EVLO stock?

ChartMill assigns a fundamental rating of 0 / 10 to EVLO.


What is the valuation status of EVELO BIOSCIENCES INC (EVLO) stock?

ChartMill assigns a valuation rating of 1 / 10 to EVELO BIOSCIENCES INC (EVLO). This can be considered as Overvalued.


Can you provide the profitability details for EVELO BIOSCIENCES INC?

EVELO BIOSCIENCES INC (EVLO) has a profitability rating of 0 / 10.